ReviewMolecules (Basel, Switzerland)2026
Small Particles, Big Impact: Inorganic Nanotechnology for Glioblastoma.
Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma Multiforme (GBM) is one of the most aggressive primary brain tumors, with a median survival of only 15-17 months. Treatment failure is largely driven by the Blood-Brain Barrier (BBB), which restricts the delivery of most conventional therapeutics and shields invasive tumor regions from systemic drugs. APPROACH: This review highlights recent advances in inorganic nanoparticles designed to cross the BBB and target GBM. These platforms, including silica-, metal-, and carbon-based nanomaterials, enable multimodal applications such as tumor imaging, localized hyperthermia, and selective induction of cancer cell death. Functionalization with targeting ligands or surface modifications further enhances tumor penetration and therapeutic efficacy. OUTLOOK: Despite promising preclinical results, clinical translation requires careful optimization of nanoparticle properties to minimize toxicity and immune clearance. Understanding these challenges provides a roadmap for the development of more effective nanomedicine strategies aimed at improving outcomes for GBM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.